- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05043324
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.
AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.
AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...
The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.
AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.
AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.
AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ho Chi Minh City, Vietnam, 700000
- Saigon Biopharma Company Limited
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients with underlying medical conditions who have been taking medications for these conditions.
- Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
- The cancer patients are stable.
- Patients with congenital or acquired immunodeficiency.
Exclusion Criteria:
- Unstable cancer patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AIDS, HIV, HBV, HCV, co-infections.
Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
|
The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
|
Experimental: "stable" cancer, acquired or congenital immunodeficiency.
Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
|
The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1)
Time Frame: - 18 months
|
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19
|
- 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2)
Time Frame: - 18 months
|
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 _ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated. |
- 18 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ayatollahi A, Bagheri S, Ashraf-Ganjouei A, Moradi K, Mohammadi MR, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clin Neuropharmacol. 2020 Sep/Oct;43(5):139-145. doi: 10.1097/WNF.0000000000000405.
- Roth A, Schaffner W, Hertel C. Phytoestrogen kaempferol (3,4',5,7-tetrahydroxyflavone) protects PC12 and T47D cells from beta-amyloid-induced toxicity. J Neurosci Res. 1999 Aug 1;57(3):399-404.
- Naran K, Nundalall T, Chetty S, Barth S. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2018 Dec 21;9:3158. doi: 10.3389/fmicb.2018.03158. eCollection 2018.
- Natural Products Structural Diversity-I Secondary Metabolites: Organization and Biosynthesis
- Herbal Support for Adrenal Function BY JAMES ROUSE, N.D.
- Majewski M. Allium sativum: facts and myths regarding human health. Rocz Panstw Zakl Hig. 2014;65(1):1-8.
- Krest I, Keusgen M. Stabilization and pharmaceutical use of alliinase. Pharmazie. 1999 Apr;54(4):289-93.
- Ullah A, Munir S, Badshah SL, Khan N, Ghani L, Poulson BG, Emwas AH, Jaremko M. Important Flavonoids and Their Role as a Therapeutic Agent. Molecules. 2020 Nov 11;25(22):5243. doi: 10.3390/molecules25225243.
- Clinical characteristics, multi-organ dysfunction, and outcomes of patients with COVID-19: A prospective observational study
- Lessel D, Kubisch C. Hereditary Syndromes with Signs of Premature Aging. Dtsch Arztebl Int. 2019 Jul 22;116(29-30):489-496. doi: 10.3238/arztebl.2019.0489.
- Jones QR, Warford J, Rupasinghe HP, Robertson GS. Target-based selection of flavonoids for neurodegenerative disorders. Trends Pharmacol Sci. 2012 Nov;33(11):602-10. doi: 10.1016/j.tips.2012.08.002. Epub 2012 Sep 12.
- Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007 Apr 9;167(7):635-41. doi: 10.1001/archinte.167.7.635.
- Vitamin C (Ascorbic Acid) Muhammad Abdullah; Radia T. Jamil; Fibi N. Attia.
- van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients. 2019 Apr 28;11(5):977. doi: 10.3390/nu11050977.
- van Gorkom GNY, Klein Wolterink RGJ, Van Elssen CHMJ, Wieten L, Germeraad WTV, Bos GMJ. Influence of Vitamin C on Lymphocytes: An Overview. Antioxidants (Basel). 2018 Mar 10;7(3):41. doi: 10.3390/antiox7030041.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVID-19 and Immunodeficiency
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on AntiCov-220 (1)
-
CelgeneCompleted
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Australia
-
CelgeneCompleted
-
CelgeneCompleted
-
CelgeneCompletedSystemic Lupus ErythematosusUnited States
-
Inter-American Development BankUniversidade Federal do Ceará; Municipal Secretary of Health, Fortaleza BrasilUnknown
-
CelgeneCompletedLupus Erythematosus, SystemicUnited States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
-
CelgeneCompletedHealthy Volunteers | Hepatic ImpairmentUnited States
-
Medical College of WisconsinNational Institute on Aging (NIA)Completed